Tag Archives | momentum stocks

Biotech Mid-Caps: The Momentum Trade is Back FMI, LOXO,XBI etc

Biotech Mid-Caps- Momentum Trade is Back ASCO Abstracts Provide Clinical Updates But as of 2 P EDT Stocks Are Being Hit By Profit Taking XBI at $92.39 Biotech mid-caps had a good week ending 5/18 as tracked by the top performing XBI which was up 2%  and over 10% in 2018 YTD. The large cap […]

Continue Reading 0

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates

Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]

Continue Reading 0

Biotechs Bounce off Bottom on Novartis Deal but Fades Later in the Day…Updates

Updates 4/11/18 Biotechs Holding Above Recent Bottom 4/6/18 FBT up 2.8% over 5 days, up 6% YTD XBI up 1.77% over 5 days, up 2.19% YTD IBB down 0.72% over 5 days, down 3.67% YTD Busted Biotechs Review In our “Busted Biotechs” article we said that the XBI trade at 83-84 would be good, now […]

Continue Reading 0

Rayno BioBeat #3…Biotech Bull Market Intact Despite Shaky Start… Update-1

4/2/18 12:30P Update Biotechs break through 2018 support levels with XBI now needs to hold December lows at $80. IBB at double bottom hit in November/December at $102 level. Watch Mid-Cap list below for sector weakness. ============== Biotech Bull Market Is Intact with Unusual Volatility Biotech Stocks Will Try to Regain Bullish Footing After A […]

Continue Reading 0

Market Rout: Biotechs Busted In Turmoil From Tariffs…Updates

Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down 4.27% Mid-caps % Up -None ========== BIG RALLY-Monday Movers 3/26/18 FBT Up 2.83%, […]

Continue Reading 0

What’s Next After Profit Taking Hits Biotech and Drug Stocks?

Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway and J.P.Morgan formed a consortium to address rising healthcare costs by trying to […]

Continue Reading 0

Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant…Update- 1/30

Update-1 10:40am EST, NASDAQ off 0.75%, S&P 500 off 0.82% Caution in biotech and healthcare stocks with disruptive announcement from J.P.Morgan, Amazon and Berkshire Hathaway with XLV down 2%. The three companies announced Tuesday that they would form an independent healthcare company to serve their employees in the U.S. Few details were provided but look for […]

Continue Reading 0

2018 Rayno Biobeat #1: Market Reversal Amidst Profit Taking…Update-1

Update-1… January 17 Dow Rallies 300 Points Market returns to the momentum mode with tax reform theme, M&A and upbeat earnings. Apple (AAPL)was a driver as a potential job creator up 1.6% on repatriation of foreign cash and contributing $350B to economy.  Technology stocks led the way up 1.45% with non-cyclical consumer goods up 1.3%; […]

Continue Reading 0

Sluggish Biotech Stocks: Five Underlying Factors Plus A Sector Shift?

MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the 2017 high fliers […]

Continue Reading 0

Biotech Hangover: Recent Earnings Feed Caution with No Near Term Catalysts

Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we posted that Risks were Rising for the 2017 biotech rally primarily because technicals were weakening […]

Continue Reading 0